Welcome to our dedicated page for Atossa Therapeutics news (Ticker: ATOS), a resource for investors and traders seeking the latest updates and insights on Atossa Therapeutics stock.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company whose news flow centers on the development of its lead investigational therapy, (Z)-Endoxifen. Company announcements frequently cover progress in breast cancer programs, regulatory interactions, intellectual property developments, and emerging opportunities in other serious diseases.
Investors following ATOS news can expect regular updates on clinical trials involving (Z)-Endoxifen, including studies in metastatic ER+/HER2- breast cancer, neoadjuvant treatment for premenopausal ER+/HER2- patients, breast cancer risk reduction strategies focused on mammographic breast density, and participation in the RECAST DCIS platform trial for hormone receptor–positive ductal carcinoma in situ. These releases often summarize trial design, early findings, and the potential implications for future registration strategies.
Atossa’s news also highlights regulatory milestones, such as FDA Type C meetings, Investigational New Drug (IND) submissions, and “Study May Proceed” letters. Additional coverage includes the FDA’s Rare Pediatric Disease designation for (Z)-Endoxifen in Duchenne Muscular Dystrophy, as well as AI-enabled research collaborations identifying new oncology indications like glioblastoma.
Another recurring theme in ATOS news is the company’s intellectual property position, including newly issued patents for enteric oral (Z)-Endoxifen formulations and methods of use in hormone-dependent breast disorders and estrogen-related conditions. Corporate updates, such as financial results, leadership appointments, and Nasdaq listing communications, provide context on Atossa’s operational and strategic direction.
By monitoring this news page, readers can review a chronological record of Atossa’s clinical, regulatory, scientific, and corporate announcements related to (Z)-Endoxifen and the company’s broader oncology and rare disease programs.
Atossa Therapeutics (Nasdaq: ATOS) announced that CEO Dr. Steven Quay will present at the LD Micro 500 virtual conference on September 4, 2020, at 9:00 AM ET. This presentation will be followed by a live Q&A session for registered investors and attendees. Additionally, Dr. Quay is available for one-on-one virtual meetings from September 1-4, 2020. Atossa focuses on developing innovative medicines for unmet medical needs, particularly in breast cancer and COVID-19. For further details, visit www.atossatherapeutics.com.
Atossa Therapeutics (Nasdaq: ATOS) has announced the enrollment of the first cohort in a Phase 1 clinical study for its nasal spray drug candidate, AT-301, aimed at treating COVID-19. The initial cohort includes 8 healthy participants who received either a placebo or the active drug. The study, conducted in Australia, is designed to evaluate the safety and tolerability of AT-301. The company aims to complete enrollment quickly, emphasizing the potential of AT-301 to act as a protective barrier against COVID-19, which could significantly impact public health if successful.
Atossa Therapeutics (NASDAQ: ATOS) announced its Q2 2020 financial results, reporting no sustainable revenue during the quarter. Operating expenses decreased by 46% to approximately $3.94 million, primarily due to reduced research and administrative costs. Atossa received approval for a Phase 1 clinical study of its COVID-19 nasal spray, AT-301, in Australia, and reported promising in vitro results for its therapies. The company has approximately $7.5 million in cash, bolstered by an additional $4.3 million raised in July.
Atossa Therapeutics (NASDAQ: ATOS) has received ethics committee approval to initiate a Phase 1 clinical study in Australia for AT-301, a nasal spray drug aimed at treating COVID-19. Enrollment is expected to start within 30 days. The drug's unique mechanism targets the nasal cavity to enhance protection and potentially lower symptoms of COVID-19. The study will assess safety and tolerability in 32 participants and could influence future FDA applications. With rising COVID-19 cases in Australia, the trial is timely and significant for public health.
Atossa Therapeutics (Nasdaq: ATOS) has announced positive interim findings from an Expanded Access study of its oral Endoxifen for breast cancer treatment, which shows no recurrence of cancer in a patient after 18 months. The treatment did not cause common side effects associated with tamoxifen, and significant reductions in tumor markers Ki-67 (50%) and ER+ cells (22%) were observed. A Phase 2 study is ongoing, focusing on newly diagnosed patients, with all interim patients showing considerable Ki-67 reduction.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) announces a webinar on July 30, 2020, hosted by CEO Dr. Steven Quay. The 30-minute event will discuss the company's breast cancer programs and advancements in two COVID-19 treatments. Registration is free via Tribe Public's website. Dr. Quay, a prominent figure in medical research, holds multiple patents and has contributed significantly to COVID-19 and breast cancer solutions. The event aims to provide insights into Atossa's progress and engage with investors.
Atossa Therapeutics (NASDAQ: ATOS) has contracted with Avance Clinical to conduct a clinical study of its nasal spray drug candidate, AT-301, aimed at treating COVID-19 in non-hospitalized patients. The double-blinded, randomized, placebo-controlled study will evaluate the safety of AT-301 in 32 healthy adults. The primary goal is to assess tolerability and local irritation, while secondary objectives include bronchospasm evaluations. Atossa plans to file for further regulatory approvals and aims to begin the study soon. The company has also filed provisional patents for AT-301.
Atossa Therapeutics (Nasdaq: ATOS) has announced positive in vitro results for its COVID-19 nasal spray, AT-301. The drug candidate demonstrated the ability to inhibit SARS-CoV-2 infectivity in VERO cells, suggesting potential efficacy in blocking virus entry into nasal cells. AT-301 aims to create a protective mucosal barrier in the nasal cavity, which could lower COVID-19 symptoms and infectivity. A Phase 1 clinical study is expected to commence soon. Atossa has filed provisional patents related to AT-301's formulation and methods of use.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) has announced the hiring of key personnel to enhance its clinical, regulatory, and chemistry manufacturing capabilities. Key hires include Heather Fraser, Ph.D., as vice president of clinical, regulatory and CMC; Natalie Farris, MS, as senior director of CMC; and Devon Payne as director of clinical operations. CEO Steven Quay emphasized that these acquisitions will accelerate the company's development pipeline, focusing on breast cancer and COVID-19 treatments, enhancing their strategic value creation efforts.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced promising in vitro test results for its COVID-19 drug candidate, AT-H201. The study indicates that AT-H201 significantly inhibits SARS-CoV-2 infectivity in VERO cells, showing it to be at least four times more potent than remdesivir and 20 times more potent than hydroxychloroquine. A provisional patent has been filed for AT-H201, although further safety and efficacy studies, as well as regulatory approvals, are required before commercialization.